Toll Free: 1-888-928-9744

REGiMMUNE Corporation - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 24 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

REGiMMUNE Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'REGiMMUNE Corporation - Product Pipeline Review - 2014', provides an overview of the REGiMMUNE Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of REGiMMUNE Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of REGiMMUNE Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of REGiMMUNE Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the REGiMMUNE Corporation's pipeline products

Reasons to buy

- Evaluate REGiMMUNE Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of REGiMMUNE Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the REGiMMUNE Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of REGiMMUNE Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of REGiMMUNE Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of REGiMMUNE Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
REGiMMUNE Corporation Snapshot 4
REGiMMUNE Corporation Overview 4
Key Information 4
Key Facts 4
REGiMMUNE Corporation - Research and Development Overview 5
Key Therapeutic Areas 5
REGiMMUNE Corporation - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
REGiMMUNE Corporation - Pipeline Products Glance 9
REGiMMUNE Corporation - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
REGiMMUNE Corporation - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
REGiMMUNE Corporation - Drug Profiles 12
RGI-2001 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
RGI-1001 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
RGI-3100 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
RGI-5000 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
RGI-4000 Series for Vaccine Adjuvants 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
REGiMMUNE Corporation - Pipeline Analysis 18
REGiMMUNE Corporation - Pipeline Products by Route of Administration 18
REGiMMUNE Corporation - Pipeline Products by Molecule Type 19
REGiMMUNE Corporation - Recent Pipeline Updates 20
REGiMMUNE Corporation - Dormant Projects 21
REGiMMUNE Corporation - Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24
List of Tables
REGiMMUNE Corporation, Key Information 4
REGiMMUNE Corporation, Key Facts 4
REGiMMUNE Corporation - Pipeline by Indication, 2014 6
REGiMMUNE Corporation - Pipeline by Stage of Development, 2014 7
REGiMMUNE Corporation - Monotherapy Products in Pipeline, 2014 8
REGiMMUNE Corporation - Phase II, 2014 9
REGiMMUNE Corporation - Preclinical, 2014 10
REGiMMUNE Corporation - Discovery, 2014 11
REGiMMUNE Corporation - Pipeline by Route of Administration, 2014 18
REGiMMUNE Corporation - Pipeline by Molecule Type, 2014 19
REGiMMUNE Corporation - Recent Pipeline Updates, 2014 20
REGiMMUNE Corporation - Dormant Developmental Projects,2014 21
REGiMMUNE Corporation, Other Locations 22 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify